Cellectis S.A. (CMVLF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 333.99 Million USD | 27.86% |
| 2022 | 261.21 Million USD | -31.63% |
| 2021 | 382.07 Million USD | -18.62% |
| 2020 | 469.47 Million USD | 0.43% |
| 2019 | 467.46 Million USD | -6.66% |
| 2018 | 500.84 Million USD | 50.46% |
| 2017 | 332.88 Million USD | 0.67% |
| 2016 | 330.67 Million USD | -11.32% |
| 2015 | 372.88 Million USD | 122.83% |
| 2014 | 167.34 Million USD | 279.34% |
| 2013 | 44.11 Million USD | -61.68% |
| 2012 | 115.1 Million USD | -12.72% |
| 2011 | 131.88 Million USD | 90.5% |
| 2010 | 69.23 Million USD | -24.2% |
| 2009 | 91.33 Million USD | 50.15% |
| 2008 | 60.83 Million USD | 12.92% |
| 2007 | 53.87 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 406.9 Million USD | 14.9% |
| 2024 Q1 | 354.13 Million USD | 6.03% |
| 2023 Q4 | 333.99 Million USD | 59.27% |
| 2023 FY | 333.99 Million USD | 27.86% |
| 2023 Q2 | 227.67 Million USD | -9.44% |
| 2023 Q3 | 209.7 Million USD | -7.89% |
| 2023 Q1 | 251.4 Million USD | -3.75% |
| 2022 Q4 | 261.21 Million USD | -6.57% |
| 2022 Q3 | 279.58 Million USD | -12.87% |
| 2022 FY | 261.21 Million USD | -31.63% |
| 2022 Q1 | 347.19 Million USD | -9.13% |
| 2022 Q2 | 320.88 Million USD | -7.58% |
| 2021 Q1 | 442.71 Million USD | -5.7% |
| 2021 Q4 | 382.07 Million USD | -7.46% |
| 2021 Q2 | 457.56 Million USD | 3.36% |
| 2021 Q3 | 412.88 Million USD | -9.76% |
| 2021 FY | 382.07 Million USD | -18.62% |
| 2020 Q1 | 471.13 Million USD | 0.78% |
| 2020 FY | 469.47 Million USD | 0.43% |
| 2020 Q3 | 484.95 Million USD | 2.59% |
| 2020 Q4 | 469.47 Million USD | -3.19% |
| 2020 Q2 | 472.69 Million USD | 0.33% |
| 2019 Q4 | 467.46 Million USD | -2.71% |
| 2019 Q2 | 505.32 Million USD | -1.29% |
| 2019 Q1 | 511.93 Million USD | 2.22% |
| 2019 FY | 467.46 Million USD | -6.66% |
| 2019 Q3 | 480.47 Million USD | -4.92% |
| 2018 Q3 | 519.79 Million USD | -2.67% |
| 2018 Q2 | 534.06 Million USD | 64.81% |
| 2018 Q1 | 324.04 Million USD | -2.65% |
| 2018 FY | 500.84 Million USD | 50.46% |
| 2018 Q4 | 500.84 Million USD | -3.65% |
| 2017 Q4 | 332.88 Million USD | -4.73% |
| 2017 Q2 | 328.63 Million USD | 0.86% |
| 2017 Q1 | 325.84 Million USD | -1.46% |
| 2017 FY | 332.88 Million USD | 0.67% |
| 2017 Q3 | 349.39 Million USD | 6.32% |
| 2016 Q3 | 352.46 Million USD | -1.71% |
| 2016 FY | 330.67 Million USD | -11.32% |
| 2016 Q2 | 358.6 Million USD | 0.56% |
| 2016 Q4 | 330.67 Million USD | -6.18% |
| 2016 Q1 | 356.59 Million USD | -4.37% |
| 2015 Q3 | 339.95 Million USD | -1.36% |
| 2015 Q4 | 372.88 Million USD | 9.69% |
| 2015 Q2 | 344.64 Million USD | -6.33% |
| 2015 FY | 372.88 Million USD | 122.83% |
| 2015 Q1 | 367.93 Million USD | 119.87% |
| 2014 Q3 | 173.67 Million USD | 196.41% |
| 2014 Q4 | 167.34 Million USD | -3.65% |
| 2014 Q2 | 58.59 Million USD | 5.7% |
| 2014 Q1 | 55.43 Million USD | 25.67% |
| 2014 FY | 167.34 Million USD | 279.34% |
| 2013 Q2 | 90.93 Million USD | 1.54% |
| 2013 Q1 | 89.55 Million USD | -22.2% |
| 2013 Q4 | 44.11 Million USD | 12.88% |
| 2013 Q3 | 39.08 Million USD | -57.02% |
| 2013 FY | 44.11 Million USD | -61.68% |
| 2012 FY | 115.1 Million USD | -12.72% |
| 2012 Q2 | 117.35 Million USD | 0.0% |
| 2012 Q4 | 115.1 Million USD | 0.0% |
| 2011 FY | 131.88 Million USD | 90.5% |
| 2011 Q4 | 131.88 Million USD | 0.0% |
| 2010 FY | 69.23 Million USD | -24.2% |
| 2010 Q4 | 69.23 Million USD | 0.0% |
| 2010 Q2 | 72.33 Million USD | 0.0% |
| 2009 FY | 91.33 Million USD | 50.15% |
| 2009 Q2 | 58.93 Million USD | 0.0% |
| 2009 Q4 | 91.33 Million USD | 0.0% |
| 2008 Q4 | 60.83 Million USD | 0.0% |
| 2008 FY | 60.83 Million USD | 12.92% |
| 2007 FY | 53.87 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 10.55 Million USD | -3064.626% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -43239.678% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -60393.123% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -69401.564% |
| Qrons Inc. | 420.00 USD | -79522431.19% |
| Rebus Holdings, Inc. | 5000.00 USD | -6679792.62% |
| Skye Bioscience, Inc. | 11.94 Million USD | -2697.179% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -156.503% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -1095.228% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -48482.027% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -16956.302% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -14458542.035% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -759.769% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -4526.117% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -437329.121% |
| SQZ Biotechnologies Company | 107.18 Million USD | -211.6% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -23223.126% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -461441.672% |
| Mesoblast Limited | 667.9 Million USD | 49.993% |
| Marizyme, Inc. | 22.01 Million USD | -1417.118% |
| Genus plc | 1.02 Billion USD | 67.539% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -24488.206% |
| Pharming Group N.V. | 462.85 Million USD | 27.84% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -9981.299% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -66827.561% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -53168.681% |
| ContraFect Corporation | 20.67 Million USD | -1515.139% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -85459.355% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -87292.656% |
| IMV Inc. | 31.33 Million USD | -965.925% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -7955.785% |
| MultiCell Technologies, Inc. | 126.22 USD | -264612981.128% |
| ONE Bio Corp. | 70.08 Million USD | -376.553% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -35443.103% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -159.898% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -77264.79% |
| Q BioMed Inc. | 3.51 Million USD | -9400.584% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -849.415% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -127731.624% |
| Biomind Labs Inc. | 73.81 Thousand USD | -452350.766% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 25.165% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -22952.507% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -1012.761% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -12061.467% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -12730.176% |
| GB Sciences, Inc. | 103.44 Thousand USD | -322781.065% |
| Alpha Cognition Inc. | 2.45 Million USD | -13520.37% |
| HST Global, Inc. | 1526.00 USD | -21886835.19% |
| CSL Limited | 38.02 Billion USD | 99.122% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -33706.254% |
| Halberd Corporation | 10.13 Thousand USD | -3296658.77% |
| Enzolytics Inc. | 361.7 Million USD | 7.661% |
| Agentix Corp. | 261.39 Thousand USD | -127675.384% |
| Resverlogix Corp. | 8.11 Million USD | -4015.769% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -17685.728% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 92.647% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -600.169% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -52114.727% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1466010.491% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -3632.136% |
| AVAX Technologies, Inc. | 7.37 Million USD | -4427.417% |
| Zenith Capital Corp. | 7410.00 USD | -4507249.946% |
| Genscript Biotech Corporation | 3.38 Billion USD | 90.137% |
| Ember Therapeutics, Inc. | 184.00 USD | -181518721.196% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -103687.571% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -127689.072% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -35892.313% |
| Kadimastem Ltd | 2.3 Million USD | -14395.791% |
| Helix BioMedix, Inc. | 3.02 Million USD | -10940.831% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -533.754% |
| BioStem Technologies, Inc. | 14.56 Million USD | -2193.873% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -584890.771% |
| LadRx Corporation | 2.3 Million USD | -14371.911% |
| Cell Source, Inc. | 195.17 Thousand USD | -171029.231% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -94350.954% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -94350.954% |
| NovAccess Global Inc. | 62.24 Thousand USD | -536454.799% |
| Affymax, Inc. | 7.44 Million USD | -4387.366% |
| Itoco Inc. | 1.4 Million USD | -23755.533% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -349058.588% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -314989.275% |
| Mobile Lads Corp. | 52.00 USD | -642297267.308% |
| CytoDyn Inc. | 11.13 Million USD | -2899.233% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -233508.421% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1867878.921% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -86545.852% |
| SYBLEU INC | 330.46 Thousand USD | -100967.163% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -81477.109% |
| International Stem Cell Corporation | 5.39 Million USD | -6096.561% |
| Bioxytran, Inc. | 137.63 Thousand USD | -242561.642% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -2126.359% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -1914.564% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -422678.014% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -38526.52% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -4343.191% |
| Neutra Corp. | 2851.00 USD | -11714899.334% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -930.657% |
| PureTech Health plc | 693.97 Million USD | 51.872% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -4038.161% |
| IXICO plc | 15.84 Million USD | -2008.033% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -3932.777% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -223.25% |
| CSL Limited | 38.02 Billion USD | 99.122% |